Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 7Gastrointestinal 3Dermatologic 3Sarcoma 2Genitourinary 2Breast 2Tumor-Agnostic 1Plasma cell 1

Conditions

Melanoma 3

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Disulfiram × Dermatologic × Clear all
NCT02101008 2023-12-13

Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy

University of Utah

Phase 2 Completed
12 enrolled 6 charts
Dermatologic

Melanoma

NCT00571116 2019-08-07

Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy

University of California, Irvine

Phase 1 Terminated
9 enrolled
Dermatologic

Melanoma

NCT00256230 2016-12-08

Disulfiram in Patients With Metastatic Melanoma

University of California, Irvine

Phase 1/2 Completed
7 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡